For the broad identification of a risk for a serious mental disorder, valid and reliable screeners are needed to detect those most likely benefitting from a time-consuming and costly in-depth clinical assessment. In the early detection of psychoses, multiple screeners for an ultra-high risk have already been suggested. Yet, no screener explicitly targets an increased risk according to the basic symptom (BS) criteria. We therefore explored the Frankfurt Complaint Questionnaire (FCQ) as a potential screener for BS in comparison to their gold-standard clinical assessment using the Schizophrenia Proneness Instrument (SPI-A/SPI-CY) by examining its convergent (agreement between screener and gold-standard, calculated by the overall percentages of agreement between FCQ and SPI-A/SPI-CY) and concurrent (degree to which a screener can identify individuals with the target condition, examined by diagnostic accuracy measures calculated using thresholds of receiver operating characteristic curves) validity. The sample consisted of 81 patients of a psychosis early detection service (41 with an at-risk mental state or psychosis, and 40 with a nonpsychotic mental disorder).
Introduction
An indicated prevention of first-episode psychosis has become increasingly important in mental health research for its potential to alter the course of psychotic disorders whose nature, i.e. neurobiological and psychosocial underpinnings, is still largely unknown (Fusar-Poli et al. 2013; Schmidt et al. 2015; Schultze-Lutter et al. 2015) . This prevention approach selectively targets patients who already seek help for mental problems including early subclinical signs and symptoms which represent primarily risk indicators or early expressions of the disorder (Mrazek and Haggerty 1994) . As the majority of first-episode psychotic disorders, and in particular schizophrenic disorders, are preceded by a prodromal phase of several years in that help might be already sought (Schultze-Lutter et al. 2010; Schaffner et al. 2012) , they offer a good starting for an indicated prevention. Thus in the past two decades, efforts have been put into identifying potential sensitive and specific clinical high risk criteria of psychosis to be assessed in clinical interviews by trained mental health professionals (Schmidt et al.
Material and Methods

Sample
The sample comprised 81 patients aged 8-40 years of the Bern Early Recognition and Intervention Centre for Mental Crises (FETZ-Bern) ( Table 2 ; demographics of the ≥16-year-olds are provided in Supplementary Table 1 ). Exclusion criteria were somatic and/or psychotropic drug-use related conditions that might account for mental problems, and insufficient reading skills in German. In total, 41 patients (50.6%) were either diagnosed with a psychotic disorder or fulfilled BS and/or ultra-high risk criteria. The remaining 40 patients (49.4%) met criteria for a nonpsychotic mental disorder or complained about only subthreshold nonpsychotic mental problems according to the Mini-International Neuropsychiatric Interview (Sheehan et al. 1998) (Table 2 ).
- Table 3 -
Instruments
SPI-A/SPI-CY were used for the assessment of clinician-rated BS (henceforth BS-SPI) and BS criteria (Table 1) , namely cognitive-perceptive BS (COPER) and cognitive disturbances (COGDIS). With each item assessing exactly one BS, SPI-A/SPI-CY rank BS on a severity scale according to the maximum frequency of their occurrence within the past three months ranging from 0 (absent=BS has not occurred in the past 3 months) to 6 (extreme=BS has occurred daily over some time within the past three months). Symptoms may also be rated as 7 (BS has always been present in same severity; trait), 8 (BS is definitely present, but its frequency of occurrence is unknown), and 9 (presence of BS can neither be unambiguously ruled in nor out). For the purpose of this study, BS-SPI were recoded according to their presence into binary items for better correspondence with the binary rated FCQitems: 1 (presence) was assigned to scores between 1-8 (i.e., all scores that clearly indicate the presence of the BS) and 0 (absence) was assigned to scores of 0 and 9 (i.e., scores clearly indicating the absence of the BS or only its ambiguous presence).
Presence and absence of self-reported BS (henceforth BS-FCQ) were assessed using the FCQ that comprises of 98 partially overlapping items referring to identical phenomena (Tables 3 and 4 ). Each item is designed as a statement describing a certain complaint, and the patient is instructed to indicate whether he/she has experienced such a complaint lately -irrespective of its frequency -by ticking either the Yes or the No box. Complaints only experienced in the past but not lately have to be indicated by ticking the Yes box and adding "formerly" next to it. For the focus of the SPI-A/SPI-CY on the past three months, these FCQ-items were considered as absent in the analyses to avoid a bias towards over-report of BS in the FCQ compared to SPI-A/SPI-CY by different assessment periods.
Assignment of BS-SPI and BS-FCQ items followed the originally described item correspondence between the FCQ and Bonn Scale for the Assessment of Basic Symptoms (Süllwold and Huber 1986 ).
Yet, as this description included only a subgroup of items however, item correspondences were complemented by Frauke Schultze-Lutter. (Tables 3 and 4 ).
Procedure
In the FETZ-Bern, patients are assessed for BS by well-trained clinical psychologists. All raters were initially trained (concordance rate with expert rating after 10 training sessions 91%) and, to further ensure high data quality over time, are continuously supervised in SPI-A/SPI-CY and SIPS assessments by Frauke Schultze-Lutter, expert in both assessments and main author of SPI-A/SPI-CY.
Patients also complete a battery of questionnaires including the FCQ. All patients (and their parents/guardians in the case of minors) provided written informed consent to the scientific use of their anonymous clinical data. The local ethical committee had approved the study.
Statistical analysis
Using SPSS 21.0, the convergent validity was calculated by the overall percentages of agreement (concordance rate; CR) between the presence of BS-SPI and BS-FCQ. Where several FCQ-items corresponded to one BS-SPI, both single FCQ-items and a compound rating (presence of any one item) were examined. To control for effects of chance, agreement on the presence of symptoms and criteria was additionally calculated using Cohen's kappa (κ) statistic. A disadvantage generally associated with use of κ is its dependence on the prevalence of an event (Byrt et al. 1993) :  tends to decrease when a response/event is rare, even if the CR is high. In the absence of a satisfactory mathematical solution to this problem, we followed the approach for the appraisal of  suggested by Burn and Weir (2011) and, additionally, calculated the prevalence index. The prevalence index reports values between -1 and 1, and is 0 when both responses are equally probable (i.e., their prevalence is 50%). According to Burn et al. (2009) , κ≥0.40 and CR≥75% are considered clinically useful. When information is contradictory, such as when CR exceeds its threshold but κ falls below it, the prevalence index should be considered. With the prevalence index approaching an absolute value of 1, the likelihood of an underestimation of  increases, and more attention should be paid to CR. Furthermore, concurrent validity (often reported as "discriminant" validity) and diagnostic accuracy of the FCQ for BS criteria were examined. The FCQ provides no information on symptom onset or frequency and so BS criteria had to be redefined to avoid a systematic bias resulting from the unequal consideration of onset and frequency in the assessment modes. To this, psychosis-risk according to SPI was re-defined as at least 1 of the binary BS included in COPER and/or at least 2 of those included in COGDIS. This re-calculation resulted in n=49 patients with COPER and n=19 with COGDIS.
To examine the concurrent validity of the FCQ-total and the FCQ criteria-relevant BS total (BScriteria-FCQ), receiver operating characteristic curves were first calculated to detect the optimal threshold for discriminating 'BS-risk' from 'no BS-risk' patients. Using these thresholds, diagnostic accuracy measures (sensitivity, specificity, positive and negative predictive values, positive and negative likelihood ratios (LR)) were then calculated. LRs guided the estimation of concurrent validity for the availability of interpretation guidelines (Jaeschke et al. 1994 ) that are missing for other accuracy measures that can only be interpreted by less reliable rules-of-thumb (Boyko 1994; Jaeschke et al. 1994 ).
An age effect was examined by sensitivity analyses in that all analyses were additionally performed on a subsample ≥16-year-olds (n=62) and compared for a systematic bias with the overall results.
Results
Criteria-relevant basic symptoms
Of the 34 BS-FCQ that correspond to criteria-relevant BS-SPI, only two visual perception disturbances (FCQ 24, 29; Table 3 ) were unequivocally reliable in terms of showing both sufficient CR of ≥75% and beyond-chance-agreement of κ>0.40. Furthermore, two other visual perception disturbances (FCQ 51, 84) might be reliably assessable with the FCQ, as they both possessed a sufficient CR and a low κ possibly caused by a high prevalence index. Altogether 15 BS-FCQ had to be regarded as an unreliable assessment despite demonstrating sufficient CRs; in these items, an insufficient κ was unlikely due to a high prevalence index. All remaining 15 BS-FCQ relevant for BS criteria showed no indication of being an adequate estimate of clinician-assessed BS-SPI as both their CRs and κ were below the threshold for clinical usefulness (Table 3) .
Basic symptom criteria
Both BS criteria, COPER and COGDIS, were overestimated by the FCQ by about 30% and 60%. Both CRs and κ fell clearly below the threshold for clinical usefulness therefore (Table 3 ).
Criteria-irrelevant basic symptoms
Of the 37 BS-FCQ not included in the BS criteria, none was unequivocally reliable in terms of showing both a sufficient CR and κ. One body perception disturbance, FCQ 18, might however reliably assess its corresponding BS-SPI (D.8), as it possessed good CR and low κ possibly caused by a high prevalence index (Table 4 ). The other body perception disturbance included in FCQ and SPI, FCQ 9, had to be regarded as unreliable despite its sufficient CR as its low κ value was unlikely caused by a high PI. All remaining 35 criteria-irrelevant BS-FCQ showed no indication of being an adequate estimate of BS-SPI, as both their CRs and κ fell below the thresholds for clinical usefulness (Table 4 ).
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Concurrent validity
Analyses of the area under the receiver operating characteristic curves of both the FCQ-total and BS criteria-FCQ revealed unsatisfactory areas under the curve of 0.737 (95% CI=0. 623-0.851, p<0.001) and 0.758 (95% CI=0. 651-0.865, p<0 .001) with regards to identifying BS-risk patients. When emphasising non-exclusion of potential risk patients (i.e. high sensitivity), the best threshold for differentiating 'BS-risk' from 'no BS-risk' were a FCQ-total ≥5 (sensitivity=0.978, specificity=0.161) and BS criteria-FCQ ≥1 (sensitivity=0. 978, specificity=0.194) . When trying to optimise both sensitivity and specificity (as reported for most screeners for UHR status), the best threshold were FCQ-total ≥24 (sensitivity=0.733, specificity=0.645) and BS criteria-FCQ ≥8 (sensitivity=0.644, specificity=0.677). The diagnostic accuracy measures of FCQ-total and BS criteria-FCQ were unsatisfactory (Table 5, Figure 1 ).
- Table 5 and Figure 1- 
Age effect
Sensitivity analyses gave no indication of an age effect. In line with the overall results, convergent and concurrent validity were mainly insufficient ( Supplementary Tables 2-4 ).
Discussion
The early detection of rare but severe conditions requires easy and broadly applicable screeners to guide the referral of appropriate patients to in-depth diagnostic assessment (Cadman et al. 1984) .
Psychosis is one such condition. In addition to reliability, an ideal screener would demonstrate excellent concurrent validity by (i) ruling in all patients with the target condition while (ii) ruling out a considerable proportion of those without it. In a practical sense then, a screener for psychosis-risk should therefore possess a sensitivity approaching 100%, a negative diagnostic LR0.1 that indicates a 'large and often conclusive' change from pre-screen to post-screen probability of the absence of psychosis-risk (Jaeschke et al. 1994), and a positive predictive value that is greatest in settings in which the prevalence of the condition is highest, i.e., greater in clinical settings than in community settings (Cadman et al. 1984) . At the same time, but secondary to the above, a screener should also possess high specificity and a positive diagnostic LR5 that indicates at least a moderate increase in the pre-screen to post-screen risk probability (Jaeschke et al. 1994) . The screen's discriminant accuracy should also not be largely mediated by confounding conditions, such as comorbid depressive or anxiety disorders (Janes and Pepe 2008), but its items/components should possess strong content and convergent validity (i.e., indeed measure the target condition) (Dawe et al. 2002) . When tested alongside the gold standard of a clinical interview, questionnaire items should highly correlate with their interview counterpart and final screen results should correlate highly with interview results (i.e., have excellent convergent validity) (Dawe et al. 2002) . In addition, the screener should assess all aspects of the condition (i.e., possess good content validity). Since the assessment of BS criteria is time-consuming and requires intensive training, and BS assessments completely rely on the patient's self-experience even during a clinical interview, we explored whether the FCQ might be used as a screener for psychosis-risk according to BS criteria. Surprisingly, the convergent validity of the assessment of BS by the FCQ was generally insufficient despite the subjective nature of BS and their general reliance on self-reporting (Schultze-Lutter 2009).
Additionally, its concurrent validity with regard to BS criteria was not satisfactory. Although BS rely less on interviewer appraisal than attenuated positive symptoms, the FCQ's concurrent validity is only as good as that reported among self-report assessments of attenuated positive symptoms when a cutoff is chosen that optimises both sensitivity and specificity (Kline and Schiffman 2014). Thus, in line with reports on differences between self-report and clinical assessments of BS and attenuated positive symptoms (Granö et al. 2011; Maß et al. 1997; Ochoa et al. 2008; Schultze-Lutter et al. 2014; Yung et al. 2009 ), we found a significant overestimation of clinician-rated BS by self-rated BS.
Only the criteria-relevant BS 'changes in colour vision' and 'micropsia, macropsia' were unequivocally valid in terms of possessing both sufficient CR and κ. Interestingly, it was also a visual perception disturbance, 'blurred vision', that previously demonstrated the highest correlation between the interview (BSABS) and self-rating (FCQ) assessment (r=0.51) (Maß et al. 1997) . This symptom however is one of the few criteria-irrelevant perception disturbances (Klosterkötter et al. 2001) and not included in SPI-A/SPI-CY; consequently, it was not analysed in our study. Furthermore, perceptual disturbances have previously shown the highest agreement between self-report and interview versions of the PROD-Screen (Granö et al. 2011 ). Contrary to our results however, acoustic perception disturbances in the PROD-Screen returned a much higher  (0.964) than visual ones (0.453).
However, PROD-Screen's acoustic perception disturbances also include hallucinations while its visual perception disturbances remain equivalent to perceptual distortions and are therefore comparable to BS (Granö et al. 2011) . Consequently, our finding of =0.320 for visual perception disturbances is more comparable to PROD-screen results than the finding of =0.249 for acoustic perception disturbances.
For all other BS included in both FCQ and SPI-A/SPI-CY, agreement between assessment modes was at most slight and therefore insufficient. The influence of item wording on convergent validity was sometimes impressive, for example,  varied between 0.090 and 0.259 for the eight alternative FCQitems assessing 'disturbances of receptive speech', and even between 0.053 and 0.301 for the three FCQ-items assessing 'disturbances of expressive speech'. The influence of wording on convergent validity has not yet been considered in the construction or translation of early detection screeners that were predominately guided by aspects of face validity. Convergent validity however might also affect the concurrent and predictive validity. The impact of different symptom formulations on convergent validity should therefore be examined for future screeners, their revisions and translations.
With regards to the two BS criteria, COPER and COGDIS,  and CRs clearly indicated an insufficient clinical usefulness of the FCQ for their assessment; the FCQ overestimated the presence of COPER by 29.6% and that of COGDIS by 58%. Thereby, COGDIS exhibited a much larger discrepancy between the results of self-reports and interviews for a psychosis-risk status than the 29.9% discrepancy reported for the PROD-screen (Granö et al. 2011) which was comparable with the results for COPER.
Even when examining a more criteria-independent assessment of the FCQ's concurrent validity, our findings were no more positive. Both negative and positive LRs were clearly insufficient according to their guidelines (Jaeschke et al. 1994) for both FCQ-total and the total of criteria-relevant BS-FCQ.
Notably, our sensitivity and specificity values were reasonably comparable to those reported for screeners for ultra-high risk status (Kline and Schiffman 2014). This indicates that LRs as measures of concurrent validity should generally be taken into account to ensure proper validation of screeners.
An advantage of our study is that we not only evaluated the concurrent validity of the FCQ for distinguishing between risk and no-risk, but also examined the FCQ's convergent validity, i.e., the extent to that it actually measures what it is supposed to measure. To date, emphasis in the examination of mainly ultra-high risk screeners has been placed on concurrent validity irrespective of convergent validity. The neglect of convergent validity has arguably resulted in distorted reports however. For example, all three scales of the Community Assessment of Psychotic Experiences (Stefanis et al. 2002) were considered accurate in discriminating ultra-high risk status (Hanssen et al. 2003; Konings et al. 2006; Mossenheb et al. 2012; Stefanis et al. 2002) , but taken in context, only the positive symptoms scale (not the negative and depressive subscales) relates to ultra-high risk criteria.
The sample size in this study was comparable to other screening evaluation studies in clinical samples In conclusion, despite their subjective nature and reliance on self-report, the assessment of BS by the FCQ appears to be no more valid than the self-report screeners of attenuated psychotic symptoms or ultra-high risk criteria and, particularly for lack of content validity, cannot be recommended as a psychosis-risk screener of BS criteria. With respect to the apparent influence of item wording on convergent validity, a future screener should first ensure items' convergent validity before investigating concurrent validity, i.e., the power to discriminate patients with and without BS criteria. Evaluation guidelines for κ: 0.00-0.20 = slight, 0.21-0.40 = fair, 0.41-0.60 = moderate, 0.61-0.80 = substantial, and 0.81-1.00 = almost perfect agreement b A high prevalence index represents a low prevalence rate, whereas a low prevalence index represents a high prevalence rate c Item was not part of the initially described correspondence between FCQ and BSABS by Süllwold & Huber (1986) ; the assignment was made by F.S.L. Supplementary Table 2 : Criteria-relevant BS: Agreement on symptom presence of self-reported BS assessed with the 'Frankfurt Complaint Questionnaire' (FCQ) and clinician-rated BS assessed with the 'Schizophrenia Proneness Instrument' (SPI-A / SPI-CY), and on presence of risk criteria "cognitive-perceptive basic symptoms" (COPER) and "cognitive disturbances" (COGDIS) for the total sample (n=81) and a subsample of ≥16-year-olds (n=62). FCQ 63, 47, 14, 19, 84, 24, 29, 45, 50, 51, 79 Evaluation guidelines for κ: 0.00-0.20 = slight, 0.21-0.40 = fair, 0.41-0.60 = moderate, 0.61-0.80 = substantial, and 0.81-1.00 = almost perfect agreement b A high prevalence index represents a low prevalence rate, whereas a low prevalence index represents a high prevalence rate c Item was not part of the initially described correspondence between FCQ and BSABS by Süllwold & Huber (1986) ; the assignment was made by F.S.L. 
FCQ items
Supplementary
